Advertisement
Collaboration › Details
Moderna–Barclays: investor conference, 201903 supply service Moderna presents at Barclays Global Healthcare Conference in Miami
Period | 2019-03-14 | |
Partner, 1st | Barclays (Group) | |
Product | Barclays Global Healthcare Conference 2019 Miami | |
Moderna, Inc.. (3/4/19). "Press Release: Moderna to Present at Upcoming Investor Conferences in March". Cambridge, MA.
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences:
> Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11, 2019 at 2:50 p.m. ET.
> Barclays Global Healthcare Conference 2019 in Miami on Thursday, March 14, 2019 at 8:30 a.m. ET.
> Oppenheimer 29th Annual Healthcare Conference in New York on Tuesday, March 19, 2019 at 8:35 a.m. ET.
A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past four years. To learn more, visit www.modernatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190304006007/en/
Source: Moderna, Inc.
Moderna Contacts:
Investors:
Lorence Kim
Chief Financial Officer
617-209-5849
Lorence.kim@modernatx.com
Media:
Jason Glashow
Head, Corporate Communications
617-674-5648
Jason.glashow@modernatx.com
Record changed: 2019-03-17 |
Advertisement
More documents for Moderna (Group)
- [1] Immatics N.V.. (9/11/23). "Press Release: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics". Cambridge, MA & Tübingen....
- [2] Moderna, Inc.. (8/26/22). "Press Release: Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform". Cambridge, MA....
- [3] Moderna, Inc.. (6/1/21). "Press Release: Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands". Albstadt....
- [4] Moderna, Inc.. (1/6/21). "Press Release: European Commission Authorizes COVID-19 Vaccine Moderna in Europe". Cambridge, MA....
- [5] Roche. (12/9/20). "Press Release: Roche Partners with Moderna to include SARS-CoV-2 Antibody Test in Ongoing COVID-19 Vaccine Trials". Basel....
- [6] Moderna, Inc.. (9/16/20). "Press Release: Moderna Announces First Commercial Organization Outside North America in Switzerland". Cambridge, MA....
- [7] Moderna, Inc.. (8/24/20). "Press Release: Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)". Cambridge, MA....
- [8] Moderna, Inc.. (7/9/20). "Press Release: Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate". Cambridge, MA & Madrid....
- [9] Lonza Ltd.. (5/1/20). "Press Release: Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) against Novel Coronavirus". Cambridge, MA & Basel....
- [10] CureVac AG. (7/31/17). "Press Release: The 5th International mRNA Health Conference to Showcase Tremendous Advances in the Development of mRNA Drugs". Tübingen & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top